

WO2005040118

Title:
**DEOXYNOJIRIMYCIN ANALOGUES AND THEIR USES AS
GLUCOSYLCERAMIDASE INHIBITORS**

Abstract:

The invention provides a new class of deoxynojirimycin analogues, or pharmaceutically acceptable salts thereof which can suitably be used for the treatment of a disease selected from the group consisting of insulin resistance, Gauger disease, inflammatory diseases, hyperpigmentation and/or inflammatory skin conditions, overweight and obesity, lysosomal storage disorders, fungal diseases, melanoma and other tumors, and microbacterial infections. The invention further provides a pharmaceutical composition comprising said deoxynojirimycin analogue, or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
6 May 2005 (06.05.2005)

PCT

(10) International Publication Number
WO 2005/040118 A1

(51) International Patent Classification⁷: **C07D 211/46**,
A61K 31/445

(21) International Application Number:
PCT/NL2004/000761

(22) International Filing Date: 29 October 2004 (29.10.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
03078395.5 29 October 2003 (29.10.2003) EP

(71) Applicant (for all designated States except US):
**ACADEMISCH ZIEKENHUIS BIJ DE UNIVER-
SITEIT VAN AMSTERDAM** [NL/NL]; Meibergdreef
15, NL-1105 AZ Amsterdam (NL).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **AERTS, Johannes,
Maria, Franciscus, Gerardus** [NL/NL]; Sandbergstraat 3,
NL-1391 EJ Abcoude (NL).

(74) Agent: **VAN WESTENBRUGGE, Andries**; Nederland-
sch Octrooibureau, Scheveningsweg 82, P.O. Box 29720,
NL-2502 LS The Hague (NL).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: DEOXYNOJIRIMYCIN ANALOGUES AND THEIR USES AS GLUCOSYLCERAMIDASE INHIBITORS

(57) Abstract: The invention provides a new class of deoxynojirimycin analogues, or pharmaceutically acceptable salts thereof which can suitably be used for the treatment of a disease selected from the group consisting of insulin resistance, Gauger disease, inflammatory diseases, hyperpigmentation and/or inflammatory skin conditions, overweight and obesity, lysosomal storage disorders, fungal diseases, melanoma and other tumors, and microbacterial infections. The invention further provides a pharmaceutical composition comprising said deoxynojirimycin analogue, or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

WO 2005/040118 A1